Shareholders will be ecstatic, with their stake up 35% over the past week following SYNLAB AG's (FRA:SYAB) latest full-year results. Statutory earnings per share fell badly short of expectations, ...

Synlab Italia has suspended all its medical diagnostic and testing services after a ransomware attack forced its IT systems to be taken offline. Part of the Synlab group that is present in 30 ...

SYNLAB AG (“SYNLAB” or “the Group”, FSE: SYAB), the leader in medical diagnostic services and specialty testing in Europe, today announced its audited FY 2023 results. The Group reports robust ...

SYNLAB AG (ETR:SYAB), is not the largest company out there, but it received a lot of attention from a substantial price increase on the XTRA over the last few months. With many analysts covering the ...

- H1'21 adjusted EBITDA of EUR 663 million compared to EUR 679 million for FY'20 - H1'21 record unlevered FCF of EUR 428 million driving major leverage ratio reduction to 1.4x - On track to exceed ...

Cinven has agreed to sell a minority stake in Synlab, a medical diagnostic services and specialty testing provider, to financial investor Elliott Advisors (UK). Munich-based Synlab provides a full ...

Laboratory services group Synlab has priced its initial public offering at 18 euros ($21.76) a share, it said on Tuesday, marking the lower end of a pricing range due to sluggish investor demand.

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Success does not always breed success. Some pandemic winners rushing to float are grabbing shortlived gains.

Cinven agreed to buy out Synlab AG for about €1.27 billion ($1.3 billion) two years after listing the German laboratory operator, which has been suffering from reduced demand for its testing ...

Laboratory services group Synlab on Monday guided investors to expect its planned initial public offering to price at the bottom of the marketing range, cutting the offer size by a quarter due to ...

While worldwide coronavirus spread and the accompanying restrictions swept the ground from under the feet of many companies, clinical laboratory SYNLAB has seen its profits go up five-fold during the ...

Synlab has set the price range for its planned initial public offering in Frankfurt at €18 to €23 a share, giving Europe’s largest laboratory services provider a market capitalization of up to €5 ...